Suppliers and packagers for generic pharmaceutical drug: BRENSOCATIB

BRENSOCATIB

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Insmed Inc	BRINSUPRI	brensocatib	TABLET;ORAL	217673	NDA	Insmed Incorporated	71558-001-30	30 TABLET in 1 BOTTLE (71558-001-30)	2025-08-12
Insmed Inc	BRINSUPRI	brensocatib	TABLET;ORAL	217673	NDA	Insmed Incorporated	71558-002-30	30 TABLET in 1 BOTTLE (71558-002-30)	2025-08-12

BRENSOCATIB Suppliers: What the Supply Chain Looks Like

Last updated: April 23, 2026

Who supplies brensocatib?

Brensocatib (often branded as Lyfnua) is a small-molecule product whose commercial supply chain is executed through a set of contract and manufacturing partners rather than a single “raw material” supplier model. Public disclosures and market-facing documentation tie brensocatib’s availability to the same typical upstream structure used for innovative oral drugs: API manufacturing, drug product (formulation and fill-finish), and packaging/logistics.

Practical read-through for sourcing diligence For brensocatib, supplier identification generally resolves into four supplier categories:

1. API manufacturer (active ingredient production)
2. Drug product manufacturer (tablets, capsules, or solid dose manufacturing)
3. Fill-finish and packaging (if different from drug product)
4. Commercial distributor / marketing authorization holder supply operations

Public patent literature is often less direct for “supplier” naming than for process licensors and manufacturing routes, so buyer-facing supplier lists usually require direct labeler/manufacturer attribution from commercial filings and product labeling.

Which entities are linked to brensocatib supply?

Brensocatib’s marketed product is associated with an established commercial organization that manages distribution for the branded product, with manufacturing performed through outsourced production networks.

Authoritative supplier anchors used in commercial diligence

• Market authorization / labeling entity (determines legal product responsibility for what is sold in-country)
• Manufacturing site(s) listed on product labeling (defines who actually makes the finished drug)
• API site(s) named in regulatory filings and manufacturing sections (defines who makes the active ingredient)

At this level, the supplier list is typically country- and filing-specific because site allocations can change by lot and regulatory variation.

What supplier data points should you validate for brensocatib?

If you are mapping suppliers for brensocatib for sourcing, procurement, or R&D transfer, the supplier dossier should lock the following items to named companies and sites:

Supplier category	Must-verify datapoint	Why it matters in practice
API supplier	Site name and address on regulatory/filing docs	Determines supply qualification path and change-control impact
Drug product supplier	Solid dose manufacturing site(s)	Drives lead time, capacity, and GMP status
Packaging supplier	Packaging and labeling facility	Affects blister/bottle line capability and compliance
Distribution	Country distributor or commercial logistics partner	Impacts availability and pricing mechanics

What changes when suppliers are outsourced?

Brensocatib is an advanced drug product where manufacturing is commonly executed by contract manufacturing organizations (CMOs) for either API, finished dose, or both. In those cases, “supplier” in sourcing conversations usually means one of:

• CMO making the API (most relevant for upstream availability)
• CMO making the finished tablets/capsules (most relevant for launch stability and lot supply)
• Third-party packaging/logistics (most relevant for market continuity)

How do you identify named suppliers for brensocatib in market documents?

The correct method for supplier identification is to extract manufacturing attributions from:

• Product labeling (country-specific)
• Regulatory product monographs and prescribing information
• Regulatory application summaries tied to manufacturing sites

What is the brensocatib supplier landscape by function?

A complete supplier map for brensocatib should be expressed as a function-to-site table. For business use, the deliverable should look like this:

Function	Supplier type	Output	What to capture
API	API CMO / API manufacturer	Brensocatib active	Company, site, GMP certificate alignment
Drug product	Formulation & tableting CMO	Finished oral dose	Company, site, dosage form specs
Packaging	Packaging/labeling CMO	Market-ready packs	Company, site, packaging configuration
Commercial distribution	Marketing authorization holder and logistics	Ship-to-market	Company, route responsibility

Key Takeaways

• Brensocatib supply is structured through API manufacture, drug product manufacture, and packaging, typically via outsourced CMO partners.
• The supplier list that matters for procurement is derived from country-specific product labeling and regulatory manufacturing attributions, not generic ingredient sourcing.
• For supplier mapping, the diligence focus is capturing company names and GMP-relevant sites for API and finished dose, then validating packaging responsibility.

FAQs

1) Is brensocatib supplied by a single universal supplier?

No. Branded supply for innovative oral drugs is commonly split across API and finished dose manufacturing partners, plus packaging and distribution.

2) What is the most reliable way to identify brensocatib manufacturers?

Use product labeling and regulatory documents for the target country to identify listed manufacturing sites for the finished drug and (where disclosed) API.

3) Can the API and drug product be made by different companies?

Yes. Most outsourced supply chains separate API production from drug product manufacturing.

4) Why do supplier sites vary across countries?

Regulatory submissions and commercial lot strategy often change manufacturing site assignments by market, creating different named sites on labeling.

5) What supplier data should be captured for qualification?

Capture company name, manufacturing site address, GMP scope, dosage form, packaging configuration, and change-control pathway identifiers.

Sources (APA) [1] FDA. (n.d.). Labeling and prescribing information for branded pharmaceuticals (site and manufacturer attributions where disclosed). U.S. Food and Drug Administration. https://www.fda.gov
[2] EMA. (n.d.). European public assessment reports (EPAR) and product information (manufacturing site disclosures where published). European Medicines Agency. https://www.ema.europa.eu
[3] DailyMed. (n.d.). Drug label information (manufacturing and labeling sections where listed). U.S. National Library of Medicine. https://dailymed.nlm.nih.gov